PLUS Therapeutics (PSTV)

[Paulness]

NEWS -- Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

Phase 1 data indicates that direct administration of 186RNL targeted radiotherapeutic is safe in patients with recurrent glioblastoma

Statistically significant overall survival benefit observed with 186RNL radiation doses over 100 Gray

NIH-funded trial moving to Phase 2 to explore expanded dosing parameters, treat larger tumor sizes, and gather additional safety and efficacy data, that will support a future registrational trial

AUSTIN, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced Phase 1 data from the ReSPECT-GBM Phase 1/2a dose escalation clinical trial evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma (GBM) in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022, being held September 9-13, 2022 in Paris, France.

“Radiation is lethal to cancer cells and rhenium-186 is an ideal radioisotope for the treatment of glioblastoma. Furthermore, the unique drug formulation allows the radiation to stay in the brain for days, if not weeks,” said Andrew J. Brenner, M.D., Ph.D., Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-GBM clinical trial. “In the ReSPECT-GBM Phase 1 trial, we achieved up to 20 times the amount of radiation compared to external beam radiation therapy, and we observed a statistically significant improvement in survival in those patients receiving a therapeutic dose of radiation compared to those that did not.”

The oral presentation titled, The ReSPECT-GBM Phase 1/2a Dose Escalation Trial of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma via Convection Enhanced Delivery (CED) & Planned Phase 2b Trial [2770], reviews data from the Phase 1 ReSPECT-GBM trial which evaluated 23 adult patients with recurrent GBM across 8 cohorts of increasing dose and treated over a seven-year period.

Key findings include:

• No dose-limiting toxicities (DLT) have been observed and the procedure is very well tolerated with a strong safety profile. Minimal systemic radiation has been observed and the majority of adverse events have been mild or moderate and considered causally unrelated to the procedure.
• Improved median overall survival (OS) rates correlated with the absorbed tumor radiation dose. When patients were stratified based on receipt of either a therapeutic or a subtherapeutic absorbed dose of radiation to the tumor, a statistically significant improvement in survival was observed. Specifically, patients receiving a therapeutic absorbed radiation dose (>100 Gray) had a median OS of 22.9 (95% CI of 8.8-42.3) months compared to those receiving a subtherapeutic absorbed radiation dose (<100 Gray) whose median OS was 5.6 months (95% CI of 1.6-9.4). Currently, three patients remain alive, all in the therapeutic group.
• Feasibility to deliver up to at least 20 times more radiation to the tumor than the standard of care, external beam radiation therapy (EBRT). A maximum of 32.2 mCi in 12.3 mL of volume has been delivered in and near the tumors, and a maximum average absorbed dose of radiation of 740 Gray has been successfully administered in a single procedure.
• Average absorbed radiation dose to the tumor increased in latter dosing cohorts with greater administered doses of Re-186 ß-particle radiation, larger drug convection enhanced delivery (CED) infusate volumes, more catheters used (up to 4 versus 1), and higher convection flow rates. In cohorts 5 and later, 82% of patients received a therapeutic radiation dose of >100Gray.
• Single-photon emission computerized tomography and (SPECT)/CT scanning were used during treatment to compute tumor coverage and dosimetry. Post treatment imaging analyses, including MRI, relative cerebral blood volume (rCBV) analysis and treatment response assessment maps (TRAMs) correlated with a positive tumor response and confirmed the presence of pseudoprogression in patients with positive tumor responses.
• ReSPECT-GBM will proceed to an NIH and U.S. Food and Drug Administration (FDA) approved Phase 2 trial in the U.S. at the current non-DLT 186RNL dose and will expand exploring higher radiation doses in larger volumes to treat larger tumors. Additionally, two or more 186RNL administrations, if indicated, will be evaluated and reviewed with the FDA, as well as expanded safety, imaging and efficacy data to support a planned future registrational trial.

“The Phase 1 data offer important and objective insight and data into 186RNL’s potential to safely prolong patient survival and suggests that there is an overall survival benefit when a 186RNL dose of more than 100 Gray is achieved,” said Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President at Plus Therapeutics. “The planned Phase 2 study using cGMP 186RNL will leverage a higher dose and volume that could potentially show a greater survival rate in patients with recurrent GBM.”

Based upon feedback from a Type C meeting with the FDA, the Company plans to initiate the ReSPECT-GBM Phase 2 trial in the second half of 2022, funded principally by the NIH. The Company intends to begin the ReSPECT-GBM Phase 2 trial utilizing cGMP 186RNL drug, which will be available in the second half of 2022. In this study, researchers plan to administer the recommended non-DLT dose of 22.3 mCi (total 186RNL activity) at a concentration of 2.5 mCi/mL in 8.8 mL total volume to patients with a tumor size of less than or equal to 20 cm3 as a starting point. Furthermore, the Company plans to evaluate further doses, including both increased dosing and multiple doses, and collect additional safety and efficacy data for the planned future registrational trial.

A copy of the presentation will be available under the Presentations tab of the Investors section of the Company’s website at the time of presentation at https://ir.plustherapeutics.com.

About Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Peter Vozzo
ICR Westwicke
[phone]
mailto://[e-mail]

Media Contact
Terri Clevenger
ICR Westwicke
[phone]
mailto://[e-mail]

[The Ultimate Choice]

That's very common in stocks that are under a dollar or sub pennies - totally legal as long as the money gets invested back into the company - my guess would be the last quarter they did not do so well so they are using that revenue to invest back into the company to kick ass and take names.

PSTV$$$$$$$$$

[The Ultimate Choice]

Phase 1 approved! And they're working on Phase II for their drug. Let's go PSTV$$$$$$$

[skichic]

Why do these guys keep selling stock, after announcing they are buying back stock?

[The Ultimate Choice]

People - It's speculation but it appears that next Thursday another PR will echo what is revealed at the conference on the 14th - Time to buy today before the price goes up!!! PSTV$$$$$$

[Paulness]

NEWS -- Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022, at 2:00 p.m. ET, and host investor meetings. The conference is being held at the Lotte New York Palace Hotel in New York City.

Investors interested in arranging an in-person meeting with the Company’s management during the conference should contact the H.C. Wainwright conference coordinator. An archived replay of the presentation will be available under the Events tab of the Plus Therapeutics website at https://www.plustherapeutics.com for 90 days following the event.

About Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Peter Vozzo
ICR Westwicke
[phone]
mailto://[e-mail]

Media Contact
Terri Clevenger
ICR Westwicke
[phone]
mailto://[e-mail]

[Paulness]

NEWS -- Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate

NIH-funded ReSPECT-GBM Phase 2 trial to start in 2022

ReSPECT-GBM Phase 2 to focus on 186RNL dose expansion, safety and efficacy data to support future registrational trial

AUSTIN, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today a summary of its Type C Clinical meeting minutes with the U.S. Food and Drug Administration (FDA) relating to its lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with recurrent glioblastoma (GBM).

The FDA and Plus Therapeutics agreed that the ReSPECT-GBM clinical trial should proceed to the planned Phase 2. The key focus areas of clinical investigation of the Phase 2 trial will be: 1) further dose exploration, including both increased dosing and multiple doses, and 2) collecting additional safety and efficacy data to inform the design of the future registrational trial. Furthermore, there was agreement that in a planned future registrational trial, overall survival should be used as the primary endpoint. The Company and the FDA also agreed to hold future meeting(s) to consider the use of external data to augment the control arm in the registrational trial.

“Our first formal FDA clinical meeting after in-licensing the Rhenium NanoLiposome radiotherapeutic platform was an important milestone for us,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “We received clear feedback and, as a result, we intend to begin the ReSPECT-GBM Phase 2 trial utilizing our cGMP 186RNL drug, which should begin later this year. We will provide more details in our moderated oral presentation at the European Society for Medical Oncology (ESMO) Congress later this month.”

In August 2022, the Company reported FDA feedback on its Chemistry, Manufacturing and Controls (CMC) focused Type C meeting. Planned cGMP production of 186RNL targeted radiotherapeutic is expected to begin in the second half of 2022 to support the ReSPECT Phase 2 clinical trial. On September 9, 2022, the ReSPECT-GBM trial principal investigator, Andrew Brenner, M.D., Ph.D., Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio, will provide a full update on the Phase 1 trial and discuss the clinical development overview during the ESMO Congress.

About Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform is centered around the precise delivery of powerful doses of rhenium, a beta-gamma emitting radioisotope that irradiates and kills tumor cells using novel microsphere and nanoliposome technologies. Our radiotherapeutics are designed and intended to potentially offer enhanced safety, efficacy and convenience for patients and healthcare providers. The 186RNL development programs for recurrent glioblastoma and leptomeningeal metastases are supported, in part, by the U.S. National Institutes of Health (NIH) and the Cancer Prevention and Research Institute of Texas (CPRIT), respectively. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Peter Vozzo
ICR Westwicke
[phone]
mailto://[e-mail]

Media Contact
Terri Clevenger
ICR Westwicke
[phone]
mailto://[e-mail]

[The Ultimate Choice]

PR this morning at 7am - FDA approves phase 2 of a cancer fighting drug created by PSTV

[akamaii]

Talk about buying at end of day. There’s gotta be leak as to how good this data will be

[The Ultimate Choice]

She'll take off her at either 2pm or at Power hour - I believe we'll see $1.10-1.20 by closing

PSTV$$$$$$$

[The Ultimate Choice]

I've been accumulating shares the past week and a half - I'm in at .88

[plustherapeutics]

Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead Drug Candidate

“We had a constructive & detailed discussion with the FDA & obtained clarity on various key CMC requirements to mitigate the risk of future delays for potential Investigational New Drug (IND) and New Drug Applications (NDA),” said Marc H. Hedrick MD, President/CEO of Plus Therapeutics. “The Company remains on track, on time & on budget to have cGMP 186RNL available in the 2nd half of 2022 for all ongoing & planned ReSPECT™ clinical trials.”

Press Release: https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-announces-summary-fda-meeting-companys-cgmp

Recent News ($17.6M CPRIT Grant & Share Repurchase Program): https://ir.plustherapeutics.com/press-releases

[plustherapeutics]

Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead Drug Candidate

“We had a constructive & detailed discussion with the FDA & obtained clarity on various key CMC requirements to mitigate the risk of future delays for potential Investigational New Drug (IND) and New Drug Applications (NDA),” said Marc H. Hedrick MD, President/CEO of Plus Therapeutics. “The Company remains on track, on time & on budget to have cGMP 186RNL available in the 2nd half of 2022 for all ongoing & planned ReSPECT™ clinical trials.”

Press Release: https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-announces-summary-fda-meeting-companys-cgmp

Recent News ($17.6M CPRIT Grant & Share Repurchase Program): https://ir.plustherapeutics.com/press-releases

[BoilerRoom]

$PSTV let’s go

[BoilerRoom]

$PSTV .96

[BoilerRoom]

$PSTV took a starter

[Paulness]

NEWS -- Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead Drug Candidate

August 29 2022 - 07:00AM
GlobeNewswire Inc.

Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today an update following receipt of formal minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) specific to Chemistry, Manufacturing and Controls (CMC). The meeting focused on the Company’s Current Good Manufacturing Practice (cGMP) clinical and commercial manufacturing process for its lead investigational targeted radiotherapeutic, BMEDA-chelated Rhenium-186 NanoLiposome (186RNL), for recurrent glioblastoma (GBM).

The FDA indicated agreement with the Company’s proposed application of cGMP guidance for radiotherapeutics, small molecule drug products and liposome drug products for Plus Therapeutics’ novel 186RNL in support of ongoing and future glioblastoma clinical trials, manufacturing scale up and commercialization. Alignment with the FDA includes support of the Company’s proposed controls and release strategy for the new drug substance and new drug product. The Company expects that this FDA feedback will apply to 186RNL used in other clinical development programs, including leptomeningeal metastases and pediatric brain cancer.

“We had a constructive and detailed discussion with the FDA and obtained clarity on various key CMC requirements to mitigate the risk of future delays for potential Investigational New Drug and New Drug Applications,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “The Company remains on track, on time and on budget to have cGMP 186RNL available in the second half of 2022 for all ongoing and planned ReSPECT™ clinical trials.”

About Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform is centered around the precise delivery of powerful doses of rhenium, a beta-gamma emitting radioisotope that irradiates and kills tumor cells using novel microsphere and nanoliposome technologies. Our radiotherapeutics are designed and intended to potentially offer enhanced safety, efficacy and convenience for patients and healthcare providers. The 186RNL development programs for recurrent glioblastoma and leptomeningeal metastases are supported, in part, by the U.S. National Institutes of Health (NIH) and the Cancer Prevention and Research Institute of Texas (CPRIT), respectively. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Peter Vozzo
ICR Westwicke
[phone]
mailto://[e-mail]

Media Contact
Terri Clevenger
ICR Westwicke
[phone]
mailto://[e-mail]

[The Ultimate Choice]

New PR this morning - In Summary, the FDA has approved the company to continue their clinical trials and studies to assist in their manufacturing of a drug to help prolong the life expectancy of individuals diagnosed with a rare brain cancer. God Bless PSTV

[The Ultimate Choice]

.90 getting tapped on the ask!!!! PSTV$$$$$$

[plustherapeutics]

Learn about our investigational, targeted radiotherapeutic, 186RNL, for adult patients with recurrent glioblastoma:

[The Ultimate Choice]

Let's go Power Hour $$$$$$

[The Ultimate Choice]

May take off after clearing .76

[Paulness]

NEWS -- Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022

AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from the Phase 1/2a ReSPECT-GBM™ dose escalation clinical trial evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022, being held September 9-13, 2022 in Paris, France.

Details of the oral presentation:



Proffered Paper abstracts accepted for oral presentation at ESMO 2022 will be published online via the ESMO website at 00:05 CEST on September 5, 2022 (6:05 p.m. EDT on September 4, 2022). For more information visit https://www.esmo.org/meetings/esmo-congress-2022.

A copy of the presentation will also be available under the Presentations tab of the Investors section of the Company’s website at the time of presentation at https://ir.plustherapeutics.com.

About Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Peter Vozzo
ICR Westwicke
[phone]
mailto://[e-mail]

Media Contact
Terri Clevenger
ICR Westwicke
[phone]
mailto://[e-mail]

[The Ultimate Choice]

We may see a $1 again today base on this morning's PR

[The Ultimate Choice]

Another wall currently at .749

[The Ultimate Choice]

Wall at .799 - once that breaks - bluer skies

[INFINITI]

True a new day disregard last post

[INFINITI]

I don’t know about that

[The Ultimate Choice]

I know it's Friday and Fridays usually suck but today is a new day

[INFINITI]

Ouch

[The Ultimate Choice]

I think it's coming

[THEMASTERS_SON]

,,,,,,,YOU’D THINK THIS MOFO WOULD BE…over$4

[The Ultimate Choice]

I think power hour will be really strong here today

[skichic]

They plan on getting $50,000,000 for 9,500,000 million shares:) or over $5.00 a share.

[INFINITI]

Cmon looks like reversal time $$$

[skichic]

They may be buying today. I would buy all I could, for under $1.00 if I was them. “ The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions and other factors, including consent of the Company’s lender. Repurchases may be made from time to time on the open market over the next 12 months, in privately negotiated transactions or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1. ”

[INFINITI]

When is the buy back supposed to happen

[INFINITI]

Biotech Turning Heads For Second Time This Week

Source: AllPennyStocks.com
This biotech company seems to hog the spotlight as of late. We covered a release earlier this week pertaining to a stock buyback program the company is initiating. Now the...

To read the full story on AllPennyStocks.com, click here.

[INFINITI]

When spellings slows down we fly again

[INFINITI]

Cmon slap that ask

[The Ultimate Choice]

Correction $2.30

[Invest-in-America]

PSTV: I'm-thinkin'-like, a Moon landing SOMETIME today, behind THIS puppy???? (Maybe???)

[The Ultimate Choice]

Just acquired a position - let's surpass the 52 week high of $2.20 $$$$$$

[INFINITI]

Load up $$$$

[INFINITI]

Nice $$$$

[crudeoil24]

Plus Therapeutics Awarded $17.6M From State Of Texas For Continued Development Of Co.'s Lead Investigational Targeted Radiotherapeutic Rhenium-186 NanoLiposome For Treatment Of Patients With Leptomeningeal Metastases
5:49 pm ET August 17, 2022 (Benzinga) Print
Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186RNL for leptomeningeal metastases.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it was awarded a $17.6 million Product Development Research grant by the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the continued development of the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with leptomeningeal metastases (LM).

"The Plus team is honored to receive this significant and esteemed award from CPRIT," said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. "We expect that the non-dilutive funding from CPRIT will come on-line next month once the award agreement is finalized and this will significantly offset our longer-term, three-year capital requirements for the advancement of our LM program."

In the second quarter of 2022, the Company completed enrollment of Cohort 1 in the ReSPECT-LM Phase 1/2a dose escalation trial (NCT05034497). 186RNL was delivered without dose limiting toxicities in this initial cohort, and the independent Data and Safety Monitoring Board has approved the plan to move ahead with Cohort 2.

"LM is one of the most devastating and aggressive late-stage cancer complications, in which the primary cancer spreads to the central nervous system. The most common solid tumor giving rise to LM is breast cancer and LM affects 3% to 5% of women already suffering with breast cancer," stated Jamil Rivers, President of METAvivor Research and Support, Inc. "The continued investment in clinical research and development for metastatic breast cancer, including leptomeningeal

[crudeoil24]

SEC filing 424B3 > 9,500,000 Shares of Common Stock. Preliminary Prospectus > 8/8/22

[INFINITI]

Let’s break $2

[INFINITI]

Looks good got in $$$$

[INFINITI]

Agree